Showing results (41-50 of 323) with videos related to
Sort By:
Pageof 33
Harefuah|August 9, 2008
[Innovations in the medical treatment of gallstones and fatty liver: FABACs (Fatty Acid Bile Acid Conjugates)]Daniel Keizman, Ilana Goldiner, Alicia Leikin-Frenkel, et al.Clinical Genitourinary Cancer|May 24, 2016
Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell CarcinomaDaniel Keizman, Maya Ish-Shalom, Avishay Sella, et al.The Oncologist|July 7, 2016
Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With SunitinibDaniel Keizman, David Sarid, Jae L Lee, et al.Clinical Investigation|November 2, 2012
The unfolding treatment landscape for men with castration-resistant prostate cancerJenny J Kim, Daniel Keizman, Samuel R Denmeade, et al.Asian Journal of Andrology|January 11, 2012
Use of androgen deprivation therapy in prostate cancer: indications and prevalenceRoisin M Connolly, Michael A Carducci, Emmanuel S AntonarakisClinical Advances in Hematology & Oncology : H&O|July 6, 2016
Challenges of conducting clinical trials of natural products to combat cancerChanning J Paller, Samuel R Denmeade, Michael A CarducciCancer Letters|September 1, 2009
Novel targeted therapeutics for metastatic castration-resistant prostate cancerEmmanuel S Antonarakis, Michael A Carducci, Mario A EisenbergerCancer Metastasis Reviews|January 9, 2014
Bone-targeting agents in prostate cancerDaniel L Suzman, Sosipatros A Boikos, Michael A CarducciInvestigational New Drugs|July 9, 2002
Endothelin-1 as a target for therapeutic intervention in prostate cancerE Scott Kopetz, Joel B Nelson, Michael A CarducciThe Journal of Urology|October 9, 2003
The evolving role of docetaxel in the management of androgen independent prostate cancerMasood A Khan, Michael A Carducci, Alan W PartinPageof 33